CNTB

Connect Biopharma Holdings Ltd. Sponsored ADR · NASDAQ

Performance

-4.44%

1W

+48.28%

1M

+50.53%

3M

+117.72%

6M

+45.76%

YTD

+53.57%

1Y

Profile

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on developing therapies to treat T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is CBP-201, an antibody to target interleukin-4 receptor alpha in development for the treatment of atopic dermatitis (AD) and asthma. The company's product candidates also comprise CBP-307, a modulator of S1P1 T cell receptor and is in development for the treatment of ulcerative colitis; and CBP-174, a peripherally acting antagonist of histamine receptor 3 in development for the treatment of pruritus associated with skin inflammation. Connect Biopharma Holdings Limited was founded in 2012 and is headquartered in San Diego, California.

Technical Analysis of CNTB 2024-04-12

Overview:

In analyzing the technical indicators for CNTB over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days.

Trend Analysis:

  • Moving Averages (MA): The 5-day MA has been consistently below the closing price, ind...
See more ...

Recent News & Updates